An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrea Necchi, Domenico Magazzu, Andrea Anichini, Daniele Raggi, Patrizia Giannatempo, Nicola Nicolai, Maurizio Colecchia, Biagio Paolini, Elisa Coradeschi, Elena Tassi, Giulia Grazia, Roberta Mortarini, Giuseppina Calareso, Elena Togliardi, Flavio Crippa, Roberto Salvioni, Alessandro M. Gianni, Pinuccia Valagussa
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590249271